300039 Stock Overview
Engages in the research, development, production, and sale of modern Chinese medicines primarily in China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Shanghai Kaibao Pharmaceutical CO.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥6.00 |
| 52 Week High | CN¥7.88 |
| 52 Week Low | CN¥4.90 |
| Beta | 0.25 |
| 11 Month Change | 18.34% |
| 3 Month Change | 11.32% |
| 1 Year Change | -16.67% |
| 33 Year Change | 30.72% |
| 5 Year Change | 38.57% |
| Change since IPO | 28.42% |
Recent News & Updates
Shareholder Returns
| 300039 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -6.1% | -5.7% | -4.5% |
| 1Y | -16.7% | -8.5% | -2.6% |
Return vs Industry: 300039 underperformed the CN Pharmaceuticals industry which returned -8.5% over the past year.
Return vs Market: 300039 underperformed the CN Market which returned -2.6% over the past year.
Price Volatility
| 300039 volatility | |
|---|---|
| 300039 Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in CN Market | 11.2% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 300039 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300039's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,325 | n/a | www.xykb.com |
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern Chinese medicines primarily in China. Its primary products include Tanreqing injection for the treatment of pneumonia, acute and chronic bronchitis, and upper respiratory tract infection; Tanreqing capsules that clears heat and detoxifies and removes phlegm; tiopronin for injection, which improves liver function of various acute and chronic hepatitis; Tiopronin enteric-coated tablets for adjuvant treatment of chronic hepatitis; and Xiongdan dropping pills that clears heat, calms liver, and improves eyesight. The company was founded in 2000 and is based in Shanghai, China.
Shanghai Kaibao Pharmaceutical CO.,Ltd Fundamentals Summary
| 300039 fundamental statistics | |
|---|---|
| Market cap | CN¥6.28b |
| Earnings (TTM) | CN¥334.72m |
| Revenue (TTM) | CN¥1.58b |
18.7x
P/E Ratio4.0x
P/S RatioIs 300039 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300039 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.58b |
| Cost of Revenue | CN¥284.14m |
| Gross Profit | CN¥1.29b |
| Other Expenses | CN¥957.99m |
| Earnings | CN¥334.72m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 25, 2024
| Earnings per share (EPS) | 0.32 |
| Gross Margin | 81.98% |
| Net Profit Margin | 21.23% |
| Debt/Equity Ratio | 0% |
How did 300039 perform over the long term?
See historical performance and comparison